Molecular allergy diagnosis enabling personalized medicine
- PMID: 39855360
- DOI: 10.1016/j.jaci.2025.01.014
Molecular allergy diagnosis enabling personalized medicine
Abstract
Allergic patients are characterized by complex and patient-specific IgE sensitization profiles to various allergens, which are accompanied by different phenotypes of allergic disease. Molecular allergy diagnosis establishes the patient's IgE reactivity profile at a molecular allergen level and has moved allergology into the era of precision medicine. Molecular allergology started in the late 1980s with the isolation of the first allergen-encoding DNA sequences. Already in 2002, the first allergen microarrays were developed for the assessment of complex IgE sensitization patterns. Recombinant allergens are used for a precise definition of personal IgE reactivity profiles, identification of genuine IgE sensitization to allergen sources for refined prescription of allergen-specific immunotherapy and allergen avoidance diagnosis of co- versus cross-sensitization, epidemiologic studies, and prediction of symptoms, phenotypes, and development of allergic disease. For example, molecular IgE sensitization patterns associated with more severe respiratory allergies, severe food allergy, and allergy to honeybee or vespids are already established. The implementation of molecular allergy diagnosis into daily clinical practice requires continuous medical education and training doctors in molecular allergy diagnosis, and may be facilitated by clinical decision support systems such as diagnostic algorithms that may take advantage of artificial intelligence.
Keywords: Allergy; allergen; allergen immunotherapy; allergic rhinitis; asthma; component-resolved diagnostics; cross-reactivity; food allergy; immunoglobulin E; microarray; molecular allergology; panallergens; precision medicine; venom allergy.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure statement P.M.M. was funded by the Deutsche Forschungs Gesellschaft (MA 4720/2; DFG, Bonn, Germany). R.V. was funded by the Danube Allergy Research Cluster program, Country of Lower Austria, by a megagrant of the government of the Russian Federation (grant 075-15-2021-632 [14.W03.31.0024]) and by a grant from the Russian Science Foundation (project 23-75-30016: “Allergen micro-array-based assessment of allergic sensitization profiles in the Russian Federation as the basis for personalized treatment and prevention of allergy [AllergochipRUS]”) regarding molecular allergen characterization. M.v.H. was funded by the Swedish Heart Lung Foundation, The Region Stockholm (ALF project, grant number FoUI-9862349), The Swedish Asthma and Allergy Foundation, The Swedish Cancer and Allergy Foundation, and the Hesselman Foundation. The authors with a Russian affiliation declare that they have prepared the article in their personal capacity and/or that they are employed at an academic/research institution where research or education is the primary function of the entity. Disclosure of potential conflict of interest: P. M. Matricardi declares research grants from Hycor, EUROIMMUN, and TFS; support for research (reagents) from Hycor, TFS, and MADX; and speaker’s fees from Hycor, TFS, and MADX outside the present work. R. Valenta declares receipt of research grants from and serves as consultant for HVD Life Sciences and Worg Pharmaceuticals. M. van Hage has received lecture fees from Thermo Fisher Scientific and AstraZeneca outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical